Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.60 |
| ▸ | C1R | P00736 | 7/20 | 0.57 |
| ▸ | F2 | P00734 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | PLG | P00747 | 1/20 | 0.57 |
| ▸ | KLK1 | P06870 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | C1S | P09871 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KLK3 | P07288 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8213595 | 0.81 | ELANE (0.73) | ELANEC1R | |
| SCHEMBL10563631 | 0.81 | KDM4E (0.54) | KMT2AATMMEN1MAPTKDM4E | |
| SCHEMBL30969124 | 0.81 | KLK7 (0.67) | ELANEC1RF2KMT2APLG | |
| SCHEMBL8205930 | 0.80 | ELANE (0.64) | ELANEC1R | |
| SCHEMBL9475884 | 0.80 | C1R (0.78) | ELANEC1RF2KMT2APLG | |
| SCHEMBL29791056 | 0.80 | C1R (0.78) | ELANEC1RF2KMT2APLG | |
| SCHEMBL9475739 | 0.78 | C1R (0.76) | ELANEC1RF2KMT2APLG | |
| SCHEMBL18963257 | 0.78 | C1R (0.76) | ELANEC1RF2KMT2APLG | |
| SCHEMBL2537274 | 0.76 | ELANE (0.73) | ELANEC1RF2KMT2APLG | |
| SCHEMBL30914649 | 0.76 | ELANE (0.73) | ELANEC1RF2KMT2APLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| EP-3174602-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016728-A2 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248756-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | ELANE 4060/4885C1R 429/4885F2 2191/4885 |
| US-10273218-B2 | BCL-3 inhibitors | BCL3, BCL2, BCL2L13 | ELANE 3860/4885C1R 526/4885F2 2192/4885 |
| US-20170267653-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | ELANE 3860/4885C1R 526/4885F2 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.